Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 9131
Gene Symbol: AIFM1
AIFM1
0.050 GeneticVariation group BEFREE Summarizing what is known today, mutations in AIFM1 are associated with a progressive disorder with myopathy, ataxia and neuropathy. 25583628 2015
Entrez Id: 9131
Gene Symbol: AIFM1
AIFM1
0.050 Biomarker group BEFREE The AIFM1 gene has been linked with COXPD6 encephalomyopathy (MIM 300816), Cowchock syndrome (MIM 310490) and X-linked deafness with neuropathy (DFNX5, MIM 300614), none of which are similar to SEMD-MR. Our results place SEMD as the third instance of a skeletal phenotype associated with a mitochondrial disease (the others being EVEN-PLUS syndrome caused by mutations of HSPA9 and CODAS syndrome due to LONP1 mutations). 27102849 2017
Entrez Id: 9131
Gene Symbol: AIFM1
AIFM1
0.050 Biomarker group BEFREE Potential candidate genes are multiple T-cell gamma receptor genes which map to the same cytogenetic interval as CMT2D neuropathy. 8872480 1996
Entrez Id: 9131
Gene Symbol: AIFM1
AIFM1
0.050 Biomarker group BEFREE Clinical spectrum of AIFM1-associated disease in an Irish family, from mild neuropathy to severe cerebellar ataxia with colour blindness. 31523922 2019
Entrez Id: 7965
Gene Symbol: AIMP2
AIMP2
0.010 AlteredExpression group BEFREE Exenatide-induced phosphorylation of p38 and CREB was also totally blocked by the PKA inhibitor and siRNA/p38<i>β</i>, but not by siRNA/p38<i>α</i> Seven-day intrathecal injections of siRNA/p38<i>β</i> (but not siRNA/p38<i>α</i>) completely blocked exenatide-induced spinal p38 activation, <i>β</i>-endorphin expression, and mechanical antiallodynia in rats with established neuropathy, although siRNA/p38<i>β</i> and siRNA/p38<i>α</i> were not antiallodynic. 28202578 2017
Entrez Id: 231
Gene Symbol: AKR1B1
AKR1B1
0.060 Biomarker group BEFREE Cellular AR mRNA/beta-actin ratios for both treated patients while on ARI therapy were approximately one-half the value observed in untreated patients with the complications of nephropathy or neuropathy. 9442813 1998
Entrez Id: 231
Gene Symbol: AKR1B1
AKR1B1
0.060 Biomarker group BEFREE Protein kinase C (PKC) and aldose reductase (AR) enzyme activities are increased in diabetes and its complications such as retinopathy, nephropathy and neuropathy. 31743046 2019
Entrez Id: 231
Gene Symbol: AKR1B1
AKR1B1
0.060 Biomarker group BEFREE Literature suggests ALR2 inhibitors such as epalrestat to possess significant potential in retinopathy and neuropathy. 30030901 2018
Entrez Id: 231
Gene Symbol: AKR1B1
AKR1B1
0.060 GeneticVariation group BEFREE Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus. 10510950 1999
Entrez Id: 231
Gene Symbol: AKR1B1
AKR1B1
0.060 Biomarker group BEFREE This review focuses on the recent studies using transgenic and gene knockout mice to analyze the role of AR in diabetic cataract and neuropathy. 12871135 2003
Entrez Id: 231
Gene Symbol: AKR1B1
AKR1B1
0.060 Biomarker group BEFREE Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. 11701599 2001
Entrez Id: 213
Gene Symbol: ALB
ALB
0.030 Biomarker group BEFREE A thorough assessment of clinical phenotype (pure cerebellar or cerebellar-plus syndrome, with or without systemic manifestations), laboratory tests (vitamin E, acanthocytosis, albumin, cholesterol, phytanic acid, lactic acid, creatine kinase, cholestanol, coenzyme Q10, alpha-fetoprotein, copper, ceruloplasmin, chitotriosidase), nerve conduction studies (presence and type of neuropathy), and an magnetic resonance imaging study (presence of cerebellar atrophy, presence and location of signal alterations) may help establish a suspected diagnosis, which should be confirmed by detecting the underlying genetic mutation. 27460185 2019
Entrez Id: 213
Gene Symbol: ALB
ALB
0.030 Biomarker group BEFREE The presence of S-sulfonated transthyretin in commercial human serum albumin solutions: Potential contribution to neuropathy. 31479652 2019
Entrez Id: 213
Gene Symbol: ALB
ALB
0.030 Biomarker group BEFREE Serum albumin (P = .002), paclitaxel dose (P = .001), and body surface area (P = .006) were statistically significantly associated with a positive rTNS change (worsening neuropathy). 29696771 2018
Entrez Id: 217
Gene Symbol: ALDH2
ALDH2
0.020 GeneticVariation group BEFREE In order to clarify whether acetaldehyde is associated with the pathogenesis of alcoholic polyneuropathy, we compared nerve conduction data as well as clinical signs and symptoms of neuropathy between alcoholics with ALDH2*2 (Lys-487) heterozygotes and those with ALDH2*1 (Glu-487) homozygotes. 15182962 2004
Entrez Id: 217
Gene Symbol: ALDH2
ALDH2
0.020 Biomarker group BEFREE As for neuropathy, the frequency of symptomatic neuropathy was higher in patients with inactive ALDH2 and usual ADH2. 15318096 2004
Entrez Id: 55626
Gene Symbol: AMBRA1
AMBRA1
0.010 Biomarker group BEFREE We found that CR ameliorates neuropathy throughout anti-inflammatory and metabolic mechanisms both in Ambra1 and in WT animals subjected to nerve injury. 30532260 2018
Entrez Id: 273
Gene Symbol: AMPH
AMPH
0.010 GeneticVariation group BEFREE The neuropathies in isolated amphiphysin-IgG autoimmunity included polyradiculoneuropathy (62%), diffuse sensory neuronopathy (35%), and facial neuropathy with gastroparesis (3%). 31624089 2019
Entrez Id: 314
Gene Symbol: AOC2
AOC2
0.010 Biomarker group BEFREE It has been speculated that production of cytotoxic products of SSAO may cause endothelial damage and thus contribute to the development of diabetic vascular complications such as retino-, nephro-, and neuropathies as a result of SSAO activity.In order to explore the possibility that high SSAO activity contributes to the development of vascular complications in diabetes, we have performed two studies in patients with Type-2 diabetes quantifying plasma SSAO activity, HbA(1c), and urinary levels of the SSAO substrate, methylamine. 12686114 2003
Entrez Id: 8639
Gene Symbol: AOC3
AOC3
0.010 Biomarker group BEFREE It has been speculated that production of cytotoxic products of SSAO may cause endothelial damage and thus contribute to the development of diabetic vascular complications such as retino-, nephro-, and neuropathies as a result of SSAO activity.In order to explore the possibility that high SSAO activity contributes to the development of vascular complications in diabetes, we have performed two studies in patients with Type-2 diabetes quantifying plasma SSAO activity, HbA(1c), and urinary levels of the SSAO substrate, methylamine. 12686114 2003
Entrez Id: 9907
Gene Symbol: AP5Z1
AP5Z1
0.010 GeneticVariation group BEFREE Here we characterize three independent fibroblast lines derived from skin biopsies of patients harbouring nonsense mutations in AP5Z1 and presenting with spastic paraplegia accompanied by neuropathy, parkinsonism and/or cognitive impairment. 26085577 2015
Entrez Id: 335
Gene Symbol: APOA1
APOA1
0.010 Biomarker group BEFREE Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency. 8686727 1996
Entrez Id: 336
Gene Symbol: APOA2
APOA2
0.010 Biomarker group BEFREE Evidence for linkage of Charcot-Marie-Tooth neuropathy (CMT1) to apolipoprotein A2 (Apo-A2). 3122561 1988
Entrez Id: 345
Gene Symbol: APOC3
APOC3
0.010 Biomarker group BEFREE Altered expression of some of the proteins of interest, transthyretin, haptaglobin, apolipoprotein C-II, apolipoprotein C-III are indicative of clinical manifestations such as neuropathy, cognitive impairment and altered lipid metabolism in SCA12. 22426495 2012
Entrez Id: 348
Gene Symbol: APOE
APOE
0.030 Biomarker group BEFREE APOE epsilon4 may not function as a susceptibility gene in sensory predominant neuropathy. 15642920 2005